Literature DB >> 33377193

Using propensity scores to estimate effects of treatment initiation decisions: State of the science.

Michael Webster-Clark1, Til Stürmer1, Tiansheng Wang1, Kenneth Man2,3, Danica Marinac-Dabic4, Kenneth J Rothman5,6, Alan R Ellis7, Mugdha Gokhale1,8, Mark Lunt9, Cynthia Girman1,10, Robert J Glynn11.   

Abstract

Confounding can cause substantial bias in nonexperimental studies that aim to estimate causal effects. Propensity score methods allow researchers to reduce bias from measured confounding by summarizing the distributions of many measured confounders in a single score based on the probability of receiving treatment. This score can then be used to mitigate imbalances in the distributions of these measured confounders between those who received the treatment of interest and those in the comparator population, resulting in less biased treatment effect estimates. This methodology was formalized by Rosenbaum and Rubin in 1983 and, since then, has been used increasingly often across a wide variety of scientific disciplines. In this review article, we provide an overview of propensity scores in the context of real-world evidence generation with a focus on their use in the setting of single treatment decisions, that is, choosing between two therapeutic options. We describe five aspects of propensity score analysis: alignment with the potential outcomes framework, implications for study design, estimation procedures, implementation options, and reporting. We add context to these concepts by highlighting how the types of comparator used, the implementation method, and balance assessment techniques have changed over time. Finally, we discuss evolving applications of propensity scores.
© 2020 John Wiley & Sons, Ltd.

Keywords:  comparative effectiveness research; propensity scores; real-world data; real-world evidence; review

Mesh:

Year:  2020        PMID: 33377193     DOI: 10.1002/sim.8866

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  12 in total

1.  Preoperative chemoradiotherapy with capecitabine and triweekly oxaliplatin versus capecitabine monotherapy for locally advanced rectal cancer: a propensity-score matched study.

Authors:  Anchuan Li; Tingxuan Huang; Rong Zheng; Xiaozhong Wang; Benhua Xu; Pan Chi; Zhihua Li
Journal:  BMC Cancer       Date:  2022-07-18       Impact factor: 4.638

2.  Effectiveness evaluation of adjuvant concurrent chemoradiotherapy for patients with positron emission tomography-staged esophageal squamous cell carcinoma after complete resection: A population-based cohort study.

Authors:  Hsin-Yuan Fang; Yu-Sen Lin; Chien-Kuang Chen; Jian-Xun Chen; Ting-Yu Lu; Tzu-Min Huang; Te-Chun Hsieh; Yu-Cheng Kuo; Chen-Yuan Lin; Ming-Yu Lien; Chi-Ching Chen; Chia-Chin Li; Chun-Ru Chien
Journal:  Thorac Cancer       Date:  2022-06-03       Impact factor: 3.223

3.  Assessing the impact of selective licencing schemes for private rental housing on mental health and well-being: protocol for a mixed-method natural experiment study in Greater London, UK.

Authors:  Jakob Petersen; Maureen Seguin; Alexandros Alexiou; Laura Cornelsen; Emilie Courtin; Steven Cummins; Dalya Marks; Matt Egan
Journal:  BMJ Open       Date:  2022-05-27       Impact factor: 3.006

4.  Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus.

Authors:  Emma M Kileel; Janet Lo; Carlos Malvestutto; Kathleen V Fitch; Markella V Zanni; Carl J Fichtenbaum; Edgar T Overton; Nwora Lance Okeke; Princy Kumar; Esau Joao; Judith A Aberg; Esteban Martinez; Judith S Currier; Pamela S Douglas; Heather J Ribaudo; Steven K Grinspoon
Journal:  Open Forum Infect Dis       Date:  2021-11-20       Impact factor: 4.423

5.  Transparency of high-dimensional propensity score analyses: Guidance for diagnostics and reporting.

Authors:  John Tazare; Richard Wyss; Jessica M Franklin; Liam Smeeth; Stephen J W Evans; Shirley V Wang; Sebastian Schneeweiss; Ian J Douglas; Joshua J Gagne; Elizabeth J Williamson
Journal:  Pharmacoepidemiol Drug Saf       Date:  2022-02-12       Impact factor: 2.732

6.  Retrospective analysis of the safety of peripherally inserted catheters versus implanted port catheters during first-line treatment for patients with diffuse large B-cell lymphoma.

Authors:  Juliette Pénichoux; Julien Rio; Leila Kammoun; Thomas Vermeulin; Louis-Ferdinand Pepin; Vincent Camus; Sydney Dubois; Florian Bouclet; Mustafa Alani; Nathalie Contentin; Stéphane Leprêtre; Aspasia Stamatoullas; Hélène Lanic; Emilie Lemasle; Anne-Lise Ménard; Pascal Lenain; Marie Gilles-Baray; Dragos Georgescu; Florian Clatot; Hervé Tilly; Fabrice Jardin
Journal:  Eur J Haematol       Date:  2022-03-21       Impact factor: 3.674

7.  Use of chlorprothixene and the risk of diabetes and major adverse cardiovascular events: A nationwide cohort study.

Authors:  Mikkel Højlund; Christina Blanner Wagner; Rikke Wesselhoeft; Kjeld Andersen; Anders Fink-Jensen; Jesper Hallas
Journal:  Basic Clin Pharmacol Toxicol       Date:  2022-02-15       Impact factor: 3.688

8.  Antidepressant use and risk of self-harm among people aged 40 years or older: A population-based cohort and self-controlled case series study.

Authors:  Yi Chai; Hao Luo; Kenneth K C Man; Wallis C Y Lau; Sherry K W Chan; Paul S F Yip; Ian C K Wong
Journal:  Lancet Reg Health West Pac       Date:  2022-08-10

9.  Consolidative chemotherapy after definitive concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients: a population based cohort study.

Authors:  Chen-Yuan Lin; Ming-Yu Lien; Chi-Ching Chen; Hsin-Yuan Fang; Yu-Sen Lin; Chien-Kuang Chen; Jian-Xun Chen; Ting-Yu Lu; Tzu-Min Huang; Te-Chun Hsieh; Shung-Shung Sun; Chia-Chin Li; Chun-Ru Chien
Journal:  BMC Gastroenterol       Date:  2022-08-10       Impact factor: 2.847

10.  Optimal radiotherapy dose in cervical esophageal squamous cell carcinoma patients treated with definitive concurrent chemoradiotherapy: A population based study.

Authors:  Chia-Chin Li; Chih-Yi Chen; Ying-Hsiang Chou; Chih-Jen Huang; Hsiu-Ying Ku; Chun-Ru Chien
Journal:  Thorac Cancer       Date:  2021-05-24       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.